ATE321529T1 - Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung - Google Patents

Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung

Info

Publication number
ATE321529T1
ATE321529T1 AT97910713T AT97910713T ATE321529T1 AT E321529 T1 ATE321529 T1 AT E321529T1 AT 97910713 T AT97910713 T AT 97910713T AT 97910713 T AT97910713 T AT 97910713T AT E321529 T1 ATE321529 T1 AT E321529T1
Authority
AT
Austria
Prior art keywords
dosage form
delayed
active ingredients
increasing release
release
Prior art date
Application number
AT97910713T
Other languages
German (de)
English (en)
Inventor
Suneel K Gupta
Diane R Guinta
Carol A Christopher
Samuel R Saks
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27363329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE321529(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE321529T1 publication Critical patent/ATE321529T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97910713T 1996-09-30 1997-09-16 Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung ATE321529T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2872696P 1996-09-30 1996-09-30
US3051496P 1996-11-12 1996-11-12
US4412197P 1997-04-22 1997-04-22

Publications (1)

Publication Number Publication Date
ATE321529T1 true ATE321529T1 (de) 2006-04-15

Family

ID=27363329

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910713T ATE321529T1 (de) 1996-09-30 1997-09-16 Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung

Country Status (11)

Country Link
EP (1) EP0932388B1 (enExample)
JP (3) JP4714313B2 (enExample)
CN (1) CN1231603A (enExample)
AT (1) ATE321529T1 (enExample)
AU (1) AU4801497A (enExample)
CA (1) CA2264852C (enExample)
DE (1) DE69735581T2 (enExample)
DK (1) DK0932388T5 (enExample)
ES (1) ES2262174T3 (enExample)
PT (1) PT932388E (enExample)
WO (1) WO1998014168A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
DE69735581T2 (de) * 1996-09-30 2007-01-25 Alza Corp., Palo Alto Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US6962997B1 (en) 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
AU2004200938B2 (en) * 1998-06-03 2006-09-14 Alza Corporation Methods and devices for providing prolonged drug therapy
KR100827254B1 (ko) * 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
AU2012232984B2 (en) * 1998-06-03 2015-10-29 Alza Corporation Methods and devices for providing prolonged drug therapy
ATE277594T1 (de) * 1998-06-03 2004-10-15 Alza Corp Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
KR20070051953A (ko) 1998-11-02 2007-05-18 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
US7300668B2 (en) 2001-10-29 2007-11-27 Massachusetts Institute Of Technology System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
JP2010229140A (ja) * 2002-02-22 2010-10-14 Shire Llc 活性物質送達系及び活性物質を保護し投与する方法
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
AU2005271522B2 (en) * 2004-08-04 2011-02-10 Alza Corporation Sustained drug release composition demonstrating an ascending zero order release pattern, methods of manufacturing such a composition
DK1791530T3 (da) 2004-08-23 2008-10-27 Pejo Iserlohn Heilmittel Und D Farmaceutisk komposition indeholdende et psykostimulerende middel
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
DK2018160T3 (da) 2006-03-16 2012-02-06 Tris Pharma Inc Modificeret depotformuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
EP1920768A1 (en) * 2006-11-10 2008-05-14 Abbott GmbH & Co. KG Solid dosage form with a film containing an active substance, as well as its method of production
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP4316488A3 (en) 2011-03-23 2024-02-28 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
WO2014174387A1 (en) 2013-03-29 2014-10-30 Wockhardt Limited Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof
DE102013014417A1 (de) 2013-08-29 2015-03-05 Klinipharm Gmbh Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
EP0094123A3 (en) * 1982-05-06 1984-07-25 THE PROCTER & GAMBLE COMPANY Therapeutic granules
DE3678644D1 (de) * 1985-08-16 1991-05-16 Procter & Gamble Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung.
LU86077A1 (fr) * 1985-09-18 1987-04-02 Pharlyse Sa Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
ATE183642T1 (de) * 1991-10-04 1999-09-15 Yoshitomi Pharmaceutical Tablette mit verzögerter freisetzung
ES2194210T3 (es) * 1996-08-16 2003-11-16 Alza Corp Forma de dosificacion para suministrar una dosis ascendente de farmaco.
DE69735581T2 (de) * 1996-09-30 2007-01-25 Alza Corp., Palo Alto Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung

Also Published As

Publication number Publication date
CA2264852A1 (en) 1998-04-09
DK0932388T5 (da) 2011-06-27
CA2264852C (en) 2005-11-01
DE69735581T2 (de) 2007-01-25
EP0932388A2 (en) 1999-08-04
JP5697893B2 (ja) 2015-04-08
EP0932388B1 (en) 2006-03-29
WO1998014168A3 (en) 1998-07-30
DK0932388T3 (da) 2006-07-17
ES2262174T3 (es) 2006-11-16
JP2014028854A (ja) 2014-02-13
CN1231603A (zh) 1999-10-13
DE69735581D1 (de) 2006-05-18
AU4801497A (en) 1998-04-24
JP2001501223A (ja) 2001-01-30
HK1127997A1 (en) 2009-10-16
PT932388E (pt) 2006-07-31
JP2010195822A (ja) 2010-09-09
WO1998014168A2 (en) 1998-04-09
JP4714313B2 (ja) 2011-06-29

Similar Documents

Publication Publication Date Title
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
PT946151E (pt) Forma de dosagem de dose crescente
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
PL334348A1 (en) Method of treating prostate diseases using vitamin d formulations of retarded and/or prolonged release
ES2123064T3 (es) Uso de melatonina en pequeñas dosis orales como somnifero.
NZ508526A (en) Opioid formulations for treating pain
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
ATE202923T1 (de) Orale dosierungsform und verfahren zur behandlung von schmerzzuständen in dermundhöhle
AU2003301190A1 (en) Administration of capsaicinoids
EP0902789A4 (enExample)
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
IL151628A0 (en) Combination therapies with vascular damaging activity
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
NO962655L (no) Deutrerte virkestoffer i transdermal applikasjon
PL348202A1 (en) Pharmaceutically active composition and dispensing device
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
DE59908258D1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
EP1690531A3 (en) Dosage form and method for administering drug
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
MD3381G2 (ro) Metodă de tratament al parotiditei cronice la copii
DE69331237D1 (de) Antiatherosclerotische mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0932388

Country of ref document: EP